Cellestia Biotech
Cellestia develops targeted therapies for cancer patients with no other options, including orphan cancers and childhood leukemia.
15 employees · est. 2014 · Basel, Switzerland
Salmedix
Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials with a focus on patient health and care
est. 2000
Salmedix is the older company (2014 vs 2000).
Side-by-Side Comparison
| Metric | Cellestia Biotech | Salmedix |
|---|---|---|
| Founded | ||
| Founded | 2014 | 2000 older |
| Headquarters | ||
| Headquarters | Basel, Switzerland | Not tracked yet |
| Employees | ||
| Employees | 15 | Not tracked yet |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Non Equity Assistance | Series C |
| Total Funding | ||
| Total Funding | $48.17M | $72.50M |
| Funding Rounds | ||
| Funding Rounds | 10 | 3 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biotech, Cancer Therapy, Targeted Therapies, Orphan Cancers, Childhood Leukemia, Autoimmune Diseases, Multi-drug Resistant Cancers, Clinical Stage Drug Candidate, CB-103, Proof-of-Concept Clinical Study, GvHD, Innovative Therapeutics, Novel Modes Of Action, IITs, Biological Activity | Oncology, Blood Cancers, Phase II Clinical Trials, Hematologic Malignancies, Drug Development, SDX-105, Healthcare Professionals, Germany, U.S., Canada, SDX-101, SDX-102, Clinical-Stage Product Candidates, David Kabakoff, San Diego |
| Website | ||
| Website | cellestia.com | salmedix.com |
About Cellestia Biotech
Cellestia Biotech is a Swiss-based biopharma startup founded in 2014. The company's mission is to develop targeted therapies for cancer patients with no other options, with a focus on orphan cancers and childhood leukemia. Their flagship drug candidate, CB-103, has shown promising results in terms o...
About Salmedix
Founded in 2000 by David Kabakoff, Salmedix is a pioneer in oncology drug development, focusing on treatments for hematologic malignancies. The company's primary product, SDX-105, has been made available in Germany to address various blood cancers, and is currently undergoing Phase II clinical trial...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Cellestia Biotech and Salmedix — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Cellestia Biotech and Salmedix — by email.
Frequently Asked Questions
Compare Cellestia Biotech with someone else
Start typing a company name or domain.